Ticker
AGLE

Price
1.27
Stock movement up
+0.03 (2.42%)
Company name
Aeglea Bio Therapeutics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsverdi
77.69M
Ent verdi
84.57M
Pris/omsetning
21.31
Pris/bok
1.26
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
-80.31%
3 års avkastning
-46.89%
5 års avkastning
-21.54%
10 års avkastning
-
Sist oppdatert: 2022-11-29

UTBYTTE

AGLE betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning21.31
Pris til bok1.26
EV i forhold til salg23.20

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall61.17M
EPS (TTM)-0.72
FCF per aksje (TTM)-0.92

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)3.65M
Bruttofortjeneste (TTM)5.06M
Driftsinntekter (TTM)-47.46M
Netto inntekt (TTM)-47.61M
EPS (TTM)-0.72
EPS (1 år fremover)-1.00

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)138.72%
Driftsmargin (TTM)-1302.05%
Fortjenestemargin (TTM)-1305.97%

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter14.64M
Netto fordringer1.01M
Samlede omløpsmidler72.60M
Goodwill0.00
Immaterielle eiendeler0.00
Eiendom, anlegg og utstyr0.00
Sum eiendeler83.17M
Leverandørgjeld2.98M
Kortsiktig/nåværende langsiktig gjeld4.92M
Sum kortsiktig gjeld16.30M
Sum gjeld21.51M
Aksjonærenes egenkapital61.66M
Netto varige driftsmidler61.66M

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)-60.45M
Kapitalutgifter (TTM)160.00K
Fri kontantstrøm (TTM)-60.61M
Utbetalt utbytte (TTM)0.00

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning-77.21%
Avkastning på eiendeler-57.24%
Avkastning på investert kapital-76.65%
Kontantavkastning på investert kapital-97.58%

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning1.31
Daglig høy1.31
Daglig lav1.22
Daglig volum272K
Tidenes høyeste11.99
1 år analytikerestimat4.43
Beta1.94
EPS (TTM)-0.72
Utbytte per aksje-
Ex-div dato-
Neste dato for resultatpresentasjon6 Mar 2023

Nedsidepotensial

Loading...
Nedsidepotensial-data
AGLES&P500
Nåværende prisfall fra toppnotering-89.41%-17.12%
Høyeste prisfall-96.81%-56.47%
Dato for høyeste fall2 Aug 20229 Mar 2009
Gj.snittlig fall fra topp-47.14%-11.46%
Gj.snittlig tid til ny topp1673 days13 days
Maks tid til ny topp1672 days1805 days
SELSKAPSOPPLYSNINGER
AGLE (Aeglea Bio Therapeutics Inc) company logo
Markedsverdi
77.69M
Markedsverdi kategori
Small-cap
Beskrivelse
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Ansatte
99
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Anthony G. Quinn
Land
USA
By
Austin
Aksjetype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
Aeglea BioTherapeutics Inc (NASDAQ: AGLE) has appointed Jeffrey M. Goldberg as president, chief executive officer, and a board member, effective November 29, 2022. Jim Kastenmayer will step down as in...
30. november 2022
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today a...
30. november 2022
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today ...
15. november 2022
Aeglea (AGLE) delivered earnings and revenue surprises of 20.83% and 72.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
3. november 2022
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today a...
3. november 2022
Gilead (GILD) signs a license agreement with Refuge Biotechnologies to use the latter's gene expression platform to develop treatments for blood cancers.
21. oktober 2022
AbbVie (ABBV) acquires UK-based DJS Antibodies Ltd to enhance its antibody research activities and strengthen the immunology portfolio.
21. oktober 2022
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today annou...
19. oktober 2022
NeuBase (NBSE) intends to reduce its existing workforce by nearly 60%. The company plans to maximize shareholder value and focus on the advancement of its platform in gene editing. Stock up.
17. oktober 2022
Aeglea BioTherapeutics Inc (NASDAQ: AGLE) received an FDA letter responding to a recently submitted protocol amendment for the Phase 1/2 trial of pegtarviliase for Classical Homocystinuria. Classical ...
4. oktober 2022
Neste side